ArticleScientific reports2017
Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials.Frontiers in immunology · 2022Pooled it
- Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients.Signal transduction and targeted therapy · 2021Trial
- Efficacy of convalescent plasma for treatment of COVID-19 in Uganda.BMJ open respiratory research · 2021Trial
- Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses.The Journal of clinical investigation · 2020Trial
- Tuberculosis treatment and cytotoxic immune signatures: a longitudinal study.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Fc effector functions in RNA viral infections: mechanisms of antiviral immunity and implications for vaccine design.Frontiers in immunology · 2026Review
- Bivalent SARS-CoV-2 spike immunization with non-replicative antibiotic resistance-free DNA vaccine induces immunity to multiple virus variants.Scientific reports · 2025Article
- Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies.Antibodies (Basel, Switzerland) · 2025Review
- A Hidden Guardian: The Stability and Spectrum of Antibody-Dependent Cell-Mediated Cytotoxicity in COVID-19 Response in Chinese Adults.Vaccines · 2025Article
- Interaction of the endogenous antibody response with activating FcγRs enhance control of Mayaro virus through monocytes.PLoS pathogens · 2025Article
- A pan-orthoebolavirus neutralizing antibody encoded by mRNA effectively prevents virus infection.Emerging microbes & infections · 2024Article
- Afucosylated anti-EBOV antibody MIL77-3 engages sGP to elicit NK cytotoxicity.Journal of virology · 2024Article
- Activating FcγRs on monocytes are necessary for optimal Mayaro virus clearance.bioRxiv : the preprint server for biology · 2024Article
- Replicon particle vaccination induces non-neutralizing anti-nucleoprotein antibody-mediated control of Crimean-Congo hemorrhagic fever virus.NPJ vaccines · 2024Article
- Article
- Natural products as a source of Coronavirus entry inhibitors.Frontiers in cellular and infection microbiology · 2024Review
- Inactivated Recombinant Rabies Virus Displaying the Nipah Virus Envelope Glycoproteins Induces Systemic Immune Responses in Mice.Vaccines · 2023Article
- Article
- A Pseudovirus-Based Entry Assay to Evaluate Neutralizing Activity against Respiratory Syncytial Virus.Viruses · 2023Article
- Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.Cell communication and signaling : CCS · 2023Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Passive immunotherapy with monoclonal antibodies (mAbs) is an efficacious treatment for Ebola virus (EBOV) infections in animal models and humans. Understanding what constitutes a protective response is critical for the development of novel therapeutic strategies. We generated an EBOV-glycoprotein-pseudotyped Human immunodeficiency virus to develop sensitive neutralizing and antibody-dependent cellular cytotoxicity (ADCC) assays as well as a bioluminescent-imaging-based mouse infection model that does not require biosafety level 4 containment. The in vivo treatment efficiencies of three novel anti-EBOV mAbs at 12 h post-infection correlated with their in vitro anti-EBOV ADCC activities, without neutralizing activity. When they were treated with these mAbs, natural killer cell (NK)-deficient mice had lower viral clearance than WT mice, indicating that the anti-EBOV mechanism of the ADCC activity of these mAbs is predominantly mediated by NK cells. One potent anti-EBOV mAb (M318) displayed unprecedented neutralizing and ADCC activities (neutralization IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.